PpProf. Peptide
Back to Peptide Library

Semaglutide + BPC-157

Weight Loss & GI ProtectionResearch-GradeCombination Blend

Last reviewed: May 28, 2026

Also Known As: Sema + BPC, GLP-1/BPC Stack, Ozempic Research Blend

Peptide Class: GLP-1 Receptor Agonist + GI Cytoprotective Blend (2-component)

Regulatory Status: Research-grade only. Semaglutide is FDA-approved as Wegovy/Ozempic but research-grade semaglutide is not the approved product. BPC-157 is FDA Category 2; WADA S0 prohibited.

What is the Semaglutide + BPC-157 blend?

The Semaglutide + BPC-157 blend is a community-derived research protocol pairing Semaglutide — a GLP-1 receptor agonist that drives 10–15% mean body weight loss in clinical trials — with BPC-157 (Body Protection Compound), a pentadecapeptide with established GI cytoprotective and tissue-repair activity in preclinical models. The mechanistic thesis: GLP-1 agonists cause nausea and GI distress in ≄44% of users and drive meaningful lean-mass loss alongside fat loss; BPC-157's gastroprotective and anabolic growth factor signaling is used to blunt the GI side-effect burden and counter muscle and connective-tissue degradation during rapid weight loss. The two compounds are run as separate vials on separate schedules — semaglutide weekly, BPC-157 daily — and are not available pre-blended due to incompatible dosing frequencies and half-lives.

Reported benefits:

  • Semaglutide-driven weight loss (~10–15% body weight over 68 weeks in STEP trials)
  • GI side-effect mitigation during semaglutide titration via BPC-157 GI cytoprotection
  • Lean-mass and connective-tissue support during caloric deficit via BPC-157 growth factor and anabolic signaling
  • Gut-wall barrier stabilization during GLP-1-mediated motility changes
  • Anti-inflammatory GI mucosal coverage via BPC-157 NF-κB modulation
  • Improved tolerability for the semaglutide titration ramp in community research reports

Common research dose: Semaglutide 0.25 mg subcutaneously once weekly (weeks 1–4) titrating to 2.4 mg once weekly by week 17+ (standard Wegovy-parallel ramp). BPC-157 250–500 mcg subcutaneously once daily (concurrent, throughout the semaglutide course).

Where to buy: Both compounds are sold separately by research peptide vendors. Neither is available as a pre-blended vial. See Verified Discount Codes → for current options.

How does the Semaglutide + BPC-157 blend work?

The blend pairs two mechanistically unrelated peptides that address different phases of GLP-1-driven weight loss. Semaglutide acts centrally and peripherally via GLP-1 receptor agonism to reduce appetite, slow gastric emptying, and drive caloric deficit. BPC-157 acts locally on gastrointestinal epithelium and connective tissue via growth factor and nitric-oxide signaling to cytoprotect the gut lining and promote tissue repair. Neither compound directly interacts with the other's pathway — the rationale is additive coverage, not pharmacodynamic synergy.

  1. Semaglutide — GLP-1 Receptor Agonism [1][5]. Semaglutide is a GLP-1 receptor agonist with ~94% homology to native human GLP-1 and a 7-day plasma half-life enabled by a C-18 fatty-acid chain that promotes albumin binding. It activates GLP-1 receptors in the hypothalamic arcuate nucleus to reduce appetite and food reward signaling; in the gastrointestinal tract it slows gastric emptying and reduces gut motility; and in the pancreas it stimulates glucose-dependent insulin secretion. The net effect is sustained caloric deficit and weight loss of 10–15% over 68 weeks in clinical trials. The same GI motility reduction that aids weight loss also drives nausea, vomiting, and constipation.
  2. BPC-157 — GI Cytoprotection and Tissue Repair [3][4]. BPC-157 (pentadecapeptide Body Protection Compound) is originally identified in human gastric juice. It activates the FAK-paxillin signaling axis, VEGFR2-Akt-eNOS pathway, and nitric oxide modulation to promote mucosal healing, angiogenesis, and cellular migration. In the GI tract specifically, BPC-157 stabilizes tight-junction proteins, reduces inflammatory cytokine cascades (including NF-κB-mediated inflammation), and promotes epithelial cell survival under stress conditions — the cellular environment created by GLP-1-mediated motility changes and elevated gastric acid exposure.
  3. Lean-Mass Protection Rationale [2][4]. Accelerated weight loss with GLP-1 agonists involves ~25–40% of total weight lost as lean mass. BPC-157 upregulates VEGF and growth factor signaling in skeletal muscle and connective tissue, promoting satellite cell activation and angiogenesis — pathways relevant to preserving or rebuilding lean tissue during caloric deficit. This is a mechanistic extrapolation; no controlled trial has tested BPC-157 as a lean-mass preservative specifically during GLP-1 therapy.
  4. Titration Rationale. Semaglutide is titrated weekly over 16–20 weeks from 0.25 mg to the 2.4 mg maintenance dose to reduce GI side-effect severity. The GI side-effect burden is highest during and immediately after each dose escalation. Researchers typically run BPC-157 continuously throughout the semaglutide titration and maintenance phases, with the GI cytoprotective activity most relevant during the early titration period when nausea and vomiting incidence peaks.
  5. No Pharmacodynamic Interaction. Semaglutide and BPC-157 do not share receptor targets or downstream pathways. The combination does not amplify the metabolic effects of semaglutide and does not interfere with GLP-1 receptor agonism. The mechanisms are parallel and non-competing.

What is the Semaglutide + BPC-157 blend used for?

Researchers use this combination for two primary purposes: GI-side-effect mitigation during semaglutide titration and lean-mass or connective-tissue protection during rapid weight loss. Both purposes are mechanistically grounded but lack controlled trial evidence for the specific combination. All applications below are extrapolated from each component's independent literature.

  1. GI Side-Effect Mitigation [1][3]. Semaglutide nausea affects ~44% of participants at the 2.4 mg dose. BPC-157's GI cytoprotective activity targets the same mucosal and enteric nervous system tissue. Researchers use BPC-157 daily throughout the semaglutide titration schedule to reduce the severity and duration of nausea, vomiting, and GI discomfort. This is the primary community-reported rationale for the combination.
  2. Lean-Mass and Connective-Tissue Protection [2][4]. GLP-1 agonists drive weight loss that is approximately 25–40% lean mass. BPC-157’s tissue-repair growth factor signaling, particularly in skeletal muscle and tendon/ligament, is used by researchers to counter the connective-tissue degradation that can accompany rapid caloric deficit. Resistance training and adequate protein are primary tools; BPC-157 is used as an adjunct.
  3. Gut-Wall Integrity During Caloric Restriction. Severe caloric restriction can reduce gut-wall integrity. BPC-157 stabilizes tight-junction proteins and promotes mucosal angiogenesis, potentially maintaining gut barrier function during the GI stress of aggressive weight-loss protocols.
  4. Post-Rapid-Weight-Loss Tendon and Joint Support. Rapid weight loss can reduce joint loading positively but may also reduce the anabolic signaling available to connective tissue. BPC-157’s tendon and ligament repair activity is used by some researchers as a connective-tissue support layer during aggressive semaglutide protocols.
  5. Appetite-Induced Protein Deficiency Cover. Semaglutide’s appetite suppression sometimes reduces protein intake below the threshold needed for lean-mass maintenance. BPC-157’s growth factor signaling is seen as a partial mechanistic compensator, though it does not substitute for adequate dietary protein.

How long does the combination take to show effects?

Semaglutide weight-loss effects accumulate over 68+ weeks in clinical trials, with meaningful weight reduction apparent by weeks 8–12 after reaching therapeutic doses. BPC-157 GI effects are reported more acutely — research-community users often report GI comfort improvement within the first 1–2 weeks of BPC-157 co-administration.

The standard semaglutide titration schedule takes 16–20 weeks to reach the 2.4 mg maintenance dose. GI side effects are most severe during and just after each dose escalation step. BPC-157 is run continuously during this period. Weight loss plateaus are commonly seen at weeks 36–52 as the body adapts. Researchers tracking lean-mass preservation typically assess body composition at 12-week intervals. BPC-157 cycles are typically 6–8 weeks with optional off periods, though some researchers run it continuously throughout the semaglutide course. The blend has no validated off-cycle schedule for the combination specifically.

How is the blend dosed?

Semaglutide and BPC-157 are dosed on separate schedules and from separate vials. Semaglutide follows a weekly titration ramp; BPC-157 is dosed daily. They are both administered subcutaneously but are not combined in the same injection or vial.

Semaglutide titration schedule (standard research protocol):

  1. Weeks 1–4. 0.25 mg subcutaneously once weekly. Initiation dose — not a therapeutic dose, purely to establish GI tolerance.
  2. Weeks 5–8. 0.5 mg subcutaneously once weekly.
  3. Weeks 9–12. 1.0 mg subcutaneously once weekly.
  4. Weeks 13–16. 1.7 mg subcutaneously once weekly.
  5. Week 17+. 2.4 mg subcutaneously once weekly (maintenance). Some researchers hold at lower doses if GI tolerance is limiting.

BPC-157 dosing (concurrent):

  1. Daily dose. 250–500 mcg subcutaneously once daily. Some researchers split into 2× daily (125–250 mcg per injection) to maintain more consistent tissue levels given BPC-157's short plasma half-life.
  2. Site. Abdomen or periumbilical region. For GI cytoprotection, abdominal injection is preferred to maximize proximity to the gastrointestinal vasculature.
  3. Cycle length. Many researchers run BPC-157 continuously alongside semaglutide, particularly during the titration phase. Others run 6–8 week BPC-157 cycles with 4–6 week off periods while continuing semaglutide.

Reconstitution notes

Semaglutide. Research-grade semaglutide is supplied as lyophilized powder. Reconstitute with bacteriostatic water for injection (BAC water). A common approach is 2 mg per vial reconstituted with 1–2 mL BAC water, yielding a concentration that allows accurate weekly dose drawing with an insulin syringe.

BPC-157. Supplied as lyophilized powder, typically 5 mg per vial. Reconstitute with bacteriostatic water. A 5 mg vial with 2 mL BAC water yields 2.5 mg/mL (2,500 mcg/mL). A 250 mcg dose requires drawing 0.1 mL (10 units on an insulin syringe); 500 mcg requires 0.2 mL (20 units).

Separate vials are required. Do not mix semaglutide and BPC-157 in the same vial. Different reconstitution volumes, concentrations, and injection schedules make separate vials the only practical approach.

Neither compound is FDA-approved in this form. Dosing is community-derived from each compound's individual research literature and the Wegovy prescribing information titration schedule (adapted for research use). There are no approved retail dosing standards for either compound as a research peptide.

Need to calculate reconstitution and draw volumes? Use the dosage calculator →.

How is the blend administered?

Both compounds are administered by subcutaneous injection using an insulin syringe. Semaglutide is injected once weekly on a consistent day; BPC-157 is injected once (or twice) daily. The injections are given separately — different syringes, different vials, potentially different times of day.

  1. Route. Subcutaneous injection for both compounds. Do not administer intravenously or intramuscularly.
  2. Semaglutide injection. Once weekly, on the same day each week. Common sites: abdomen (at least 2 inches from navel), front of thigh, or upper arm. Rotate sites weekly.
  3. BPC-157 injection. Once daily (or split twice daily). Abdomen preferred for GI cytoprotection purposes. Rotate sites daily.
  4. Time of day. Semaglutide: any consistent time works. BPC-157: morning or consistent daily timing. Semaglutide’s weekly injection day should not be changed without re-establishing a new consistent day.
  5. With or without food. Semaglutide: independent of meals (injected, not oral). BPC-157: independent of meals.
  6. Site rotation. Alternate abdomen, thigh, and upper arm for semaglutide. Alternate left and right abdominal quadrants for daily BPC-157. Maintain at least 1 inch from previous injection sites.
  7. Reconstitution. Use bacteriostatic water for injection. Swirl gently — do not shake either compound. Semaglutide is particularly sensitive to agitation.
  8. Missed semaglutide dose. If missed by ≤5 days, administer as soon as possible. If more than 5 days have elapsed, skip and administer on the next scheduled day. Do not double-dose.
  9. Missed BPC-157 dose. Resume on the next scheduled day. Do not double-dose.

What does this blend stack well with?

The Semaglutide + BPC-157 combination is already a 2-compound protocol with meaningful side-effect burden from semaglutide. Additional peptide stacking should be conservative. The most evidence-based additions are non-pharmacological (resistance training, protein intake) and targeted peptide additions with clear mechanistic justification.

  1. Resistance training + 1.2–1.6 g/kg protein. The primary evidence-based strategy for lean-mass preservation during GLP-1 weight loss. Mechanical loading is required for proper muscle remodeling — peptides are adjuncts, not substitutes.
  2. Tirzepatide + BPC-157 (alternative GLP-1 backbone). Tirzepatide is a dual GIP/GLP-1 receptor agonist with superior weight-loss efficacy in trials (~20–22% vs ~15%). Researchers choosing tirzepatide over semaglutide for the GLP-1 component apply the same BPC-157 rationale. See Tirzepatide + BPC-157 →.
  3. Cagrilintide (amylin analog for GLP-1 amplification). Cagrilintide combined with semaglutide (CagriSema) has shown >20% weight loss in phase 3 trials. BPC-157 co-administration rationale would apply equally, with compounded GI burden from dual agonism. Research-community use is early-stage.
  4. Wolverine Stack (BPC-157 + TB-500) for connective-tissue support. Adding TB-500 to the BPC-157 component broadens connective-tissue coverage via actin-mediated cellular migration. Relevant for researchers experiencing tendon or joint stress during rapid weight loss or who are adding progressive resistance training. See Wolverine Stack →.
  5. Avoid: compounding GI-burden compounds. Do not stack additional GI-active peptides (e.g., high-dose GHRPs like GHRP-6) with semaglutide. Cumulative nausea and GI distress risk compounds significantly.
  6. Avoid: full-dose BPC-157 duplication. If running the Wolverine Stack (which contains BPC-157), do not additionally dose standalone BPC-157 vials on top — the Wolverine BPC-157 component is sufficient coverage.

What are the side effects of the Semaglutide + BPC-157 blend?

The side-effect profile of the combination is dominated by semaglutide's well-documented GI effects, which are among the most significant of any research peptide. BPC-157’s individual side-effect profile is mild. There is no controlled trial of the combination, so interaction-level side-effect data does not exist. The list below draws from each component’s independent literature plus research-community reports.

Common (most users on semaglutide)

  1. Nausea. The most common semaglutide side effect (≄44% in STEP 1). Most severe during titration dose escalations. BPC-157 co-administration is the primary community strategy for mitigation.
  2. Vomiting. Reported in ≄25% of participants in STEP 1. Typically peaks 1–3 days after each dose escalation.
  3. Diarrhea or constipation. GLP-1-mediated gut motility changes produce both. Constipation is more common at higher doses; diarrhea more common during titration.
  4. Injection-site reactions (BPC-157). Mild redness or irritation at BPC-157 injection sites. The most commonly reported BPC-157 side effect.
  5. Reduced appetite and fatigue. Expected pharmacological effects of semaglutide. Relevant for training protocols alongside the research cycle.

Less common

  1. Lean-mass loss. 25–40% of weight lost is lean mass without resistance training and adequate protein. Not a side effect in the classic sense but a significant compositional concern during aggressive weight loss.
  2. Heartburn and GERD-like symptoms. Slowed gastric emptying increases gastric acid contact time with the esophagus.
  3. Headache (BPC-157). Typically mild, transient, and more common in the first 1–2 weeks of BPC-157 initiation.
  4. Hair thinning (telogen effluvium). Reported in some individuals undergoing rapid weight loss. Related to caloric restriction and nutritional stress, not directly to semaglutide pharmacology.

Serious (rare or theoretical)

  1. Semaglutide: pancreatitis risk. Acute pancreatitis is a labeled warning for GLP-1 receptor agonists. Risk is low but documented. Researchers with personal or family history of pancreatitis should not use semaglutide.
  2. Semaglutide: thyroid C-cell tumors (rodent signal). Semaglutide carries an FDA boxed warning based on rodent carcinogenicity data. Not confirmed in humans, but the warning applies to all GLP-1 receptor agonists. Individuals with personal or family history of MEN2 or medullary thyroid carcinoma should not use semaglutide.
  3. BPC-157: theoretical mitogenic risk. BPC-157 promotes angiogenesis and growth factor signaling. The theoretical concern about tumor promotion has not produced signals in preclinical studies, but controlled human safety data are limited.
  4. Anti-doping: WADA S0 (BPC-157). BPC-157 is on the WADA prohibited list under Section S0. Research-grade semaglutide is not a tested-for substance in most sport anti-doping programs, but its use in competitive contexts raises ethical questions under spirit-of-sport provisions. Tested athletes should not use either compound without consulting their sport's anti-doping authority.

The combined safety profile of research-grade semaglutide + BPC-157 has not been formally studied. Most evidence comes from FDA-approved semaglutide clinical trial data (Wegovy/Ozempic) for semaglutide, and preclinical animal models plus research-community reports for BPC-157. Research-grade semaglutide is not manufactured under GMP; purity and potency are unverified relative to the pharmaceutical product.

Does the blend interact with other drugs?

Semaglutide has several documented drug interactions, primarily related to its effect on gastric emptying and oral drug absorption. BPC-157 has no well-documented systemic drug interactions. The most clinically relevant concerns are listed below.

  1. Oral medications with narrow therapeutic windows. Semaglutide delays gastric emptying, which can alter the absorption rate and peak concentration of oral drugs. Of particular concern: oral anticoagulants (warfarin), oral hypoglycemic agents, oral contraceptives, and cyclosporine. Timing of oral medications relative to semaglutide injection may need adjustment.
  2. Insulin and other antidiabetic agents. Semaglutide lowers blood glucose. Co-administration with insulin or sulfonylureas increases hypoglycemia risk. Dose adjustment is often required.
  3. Anticoagulants (warfarin, DOACs). Both the gastric-emptying effect of semaglutide (altering oral warfarin absorption) and the theoretical angiogenic activity of BPC-157 raise interaction concerns. No documented clinical events with BPC-157 specifically.
  4. NSAIDs. BPC-157 is used in some protocols specifically to protect GI mucosa in NSAID users. However, chronic NSAID use during a semaglutide cycle compounds GI mucosal irritation risk from two directions. NSAIDs should be minimized during semaglutide use.
  5. Alcohol. Alcohol increases acute pancreatitis risk, which overlaps with semaglutide’s labeled pancreatitis warning. Alcohol should be minimized during semaglutide use.
  6. GLP-1 agonist combinations. Do not use semaglutide concurrently with other GLP-1 receptor agonists (liraglutide, dulaglutide, tirzepatide’s GLP-1 component). Compounded GI burden and receptor over-activation are the concerns.

How should the blend be stored?

  1. Semaglutide (lyophilized powder): -20°C long-term. Refrigerate at 2–8°C once reconstituted. Use reconstituted semaglutide within 28 days.
  2. BPC-157 (lyophilized powder): -20°C long-term, 2–8°C for short-term (refrigerated). Use within 30 days of reconstitution.
  3. Reconstitution for both: bacteriostatic water for injection (BAC water). Swirl gently — do not shake. Semaglutide is particularly sensitive to agitation and should never be shaken.
  4. Do not freeze reconstituted solutions. Freezing causes peptide aggregation and loss of activity.
  5. Protect both compounds from light. Store in original containers or amber vials away from direct sunlight.
  6. Store semaglutide and BPC-157 in separate labeled vials. Do not pool reconstituted solutions.
  7. Discard any solution that is cloudy, discolored, or contains particulate matter.

Where to source Semaglutide + BPC-157

Neither compound is FDA-approved in research-grade form, and they are not available as a pre-blended vial. Researchers source two separate vials from specialty peptide vendors. The vendors highlighted below carry research-grade semaglutide and BPC-157 and have been vetted for transparent third-party testing and traceable documentation.

EZ Peptides10% off
Editor's Pick

Stocks research-grade semaglutide and BPC-157 separately

Click to copy code

Shop EZ Peptides →
Glacier Aminos10% off
Editor's Pick

Click to copy code

Shop Glacier Aminos →
Peptide Partners10% off
Editor's Pick

Click to copy code

Shop Peptide Partners →

See all verified vendors →

What are the limitations of this research area?

The Semaglutide + BPC-157 combination is entirely community-derived. No controlled trial has tested this pairing. Semaglutide has an extensive clinical evidence base as an FDA-approved pharmaceutical, but research-grade semaglutide is not the same product. BPC-157 has no human clinical trial data for any indication.

No controlled trial of the combination exists. All efficacy and safety claims for the pairing are mechanistic extrapolations from semaglutide's clinical trial data (Wegovy/Ozempic) and BPC-157's preclinical literature. The two compounds have never been co-administered in a randomized controlled trial.

Research-grade semaglutide is not the approved pharmaceutical. Wegovy and Ozempic are manufactured under pharmaceutical GMP with documented sterility, purity, and potency. Research-grade semaglutide from peptide vendors carries none of those assurances. Third-party HPLC and endotoxin testing from the vendor is the minimum quality bar.

BPC-157 has no approved human clinical trial data. All BPC-157 evidence is preclinical (animal models). No phase 1, 2, or 3 human trial has been completed for BPC-157 in any indication. Extrapolating from rodent GI cytoprotection to human GLP-1 side-effect mitigation involves multiple unvalidated assumptions.

Lean-mass claims are mechanistically plausible, not evidenced. BPC-157's growth factor and anabolic signaling is documented in animal models. There is no human trial — and certainly no trial specific to GLP-1 co-administration — demonstrating that BPC-157 reduces lean-mass loss during semaglutide-driven weight loss.

Anti-doping status. BPC-157 is on the WADA prohibited list (Section S0). Research-grade semaglutide is not manufactured for pharmaceutical use. Tested athletes should not use either compound.

FDA regulatory status. Research-grade semaglutide is not the FDA-approved product. BPC-157 sits on the FDA Category 2 bulk drug substance list and cannot be compounded for human use under 503A or 503B pharmacies. Both compounds are sold for laboratory research use only.

Semaglutide + BPC-157 FAQ

What is the Semaglutide + BPC-157 blend?

The Semaglutide + BPC-157 blend is a community-derived research protocol pairing Semaglutide (a GLP-1 receptor agonist) with BPC-157 (Body Protection Compound). The rationale is mechanistic: Semaglutide drives meaningful weight loss but frequently causes nausea, vomiting, and GI distress, and accelerated weight loss is associated with lean-mass loss. BPC-157's established GI cytoprotective activity and tissue-repair signaling are used by researchers to blunt the GI side-effect burden and counter the muscle and connective-tissue loss that accompanies rapid caloric deficit.

Is this blend available as a single pre-mixed vial?

No. Semaglutide and BPC-157 have incompatible dosing schedules and very different half-lives — Semaglutide is dosed weekly (7-day half-life); BPC-157 is dosed daily (short plasma half-life under 30 minutes). They are not formulated together in a single vial by any major vendor. Researchers run them as two separate vials, reconstituted and injected independently according to each compound's schedule.

Does BPC-157 actually reduce GLP-1 nausea?

There is no controlled trial of BPC-157 as an adjunct to semaglutide or any GLP-1 agonist. The rationale is mechanistic: BPC-157 has extensive preclinical evidence of cytoprotective activity in gastric and intestinal epithelium — it reduces inflammation, stabilizes mucosal integrity, and modulates enteric nervous system signaling, which is the same tissue network involved in GLP-1-induced nausea. Researchers use it for this purpose, but controlled evidence for the specific combination does not exist.

How does research-grade semaglutide differ from Wegovy and Ozempic?

Wegovy and Ozempic are FDA-approved pharmaceutical products (sema­glutide) manufactured to GMP standards with documented purity, potency, and sterility. Research-grade semaglutide sold by peptide vendors is not the FDA-approved product — it is not manufactured under GMP, is not sterile by pharmaceutical standards, and is sold for laboratory use only. The molecular structure is the same, but the regulatory status, manufacturing controls, and clinical oversight are entirely different.

Is BPC-157 FDA-approved?

No. BPC-157 sits on the FDA Category 2 bulk drug substance list — it is designated as a substance that lacks adequate evidence of clinical use and cannot be compounded for human use under Section 503A or 503B pharmacies. It is sold as a research chemical for laboratory use only. BPC-157 is also on the WADA prohibited list under Section S0 (non-approved substances). Tested athletes should not use BPC-157 in any form.

Will I lose muscle on semaglutide?

Studies of semaglutide and tirzepatide in clinical trials have documented that approximately 25–40% of weight lost is lean mass, depending on baseline body composition, protein intake, and training status. Resistance training and adequate protein intake (1.2–1.6 g/kg) are the primary evidence-based tools for attenuating lean-mass loss. BPC-157 is used by researchers for its tissue-repair and anabolic signaling, but there is no controlled trial demonstrating that BPC-157 specifically preserves lean mass during GLP-1-driven weight loss.

Where can I source research-grade semaglutide and BPC-157?

Both compounds are available separately from research peptide vendors. Because they are not pre-blended, researchers source two vials independently. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes →.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Ida S, Kaneko R, Murata K, et al. Effects of GLP-1 receptor agonists on lean body mass. Diabetes Obes Metab. 2021. https://pubmed.ncbi.nlm.nih.gov/34480530/
  3. Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.627533/full
  4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Sports Health. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
  5. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. https://pubmed.ncbi.nlm.nih.gov/33812489/

Published Studies

No controlled trial exists for the Semaglutide + BPC-157 combination. The studies below are the key peer-reviewed sources for each component's mechanism and efficacy, and the empirical basis for the blend's mechanistic rationale.

New England Journal of Medicine · 2021Open Access
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) →

Wilding JPH, Batterham RL, Calanna S, et al.

The landmark STEP 1 trial (n=1,961) established once-weekly subcutaneous semaglutide 2.4 mg as producing ~15% mean body weight reduction over 68 weeks versus ~2.4% with placebo. Nausea was reported in 44.2% of participants and vomiting in 24.8%, predominantly in the titration phase — the GI side-effect profile that drives co-administration of BPC-157 in research settings. The trial enrolled adults without type 2 diabetes, making it the foundational weight-management efficacy data for research-grade semaglutide protocols.

Diabetes, Obesity and Metabolism · 2021Paywalled
Lean Body Mass Changes with Semaglutide: Evidence from the STEP Trials and Real-World Data →

Ida S, Kaneko R, Murata K, et al.

Analysis of lean-mass composition changes during GLP-1 agonist therapy. GLP-1 receptor agonist-driven weight loss consistently involves meaningful lean-mass reduction, estimated at 25–40% of total weight lost across trials. This lean-mass loss — encompassing skeletal muscle and connective tissue — is the mechanistic rationale for pairing a tissue-repair peptide like BPC-157 with semaglutide protocols. The paper underscores the importance of resistance training and protein intake as primary countermeasures.

Frontiers in Pharmacology · 2021Open Access
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing →

Sikiric P, Hahm KB, Blagaic AB, et al.

Comprehensive review of BPC-157's wound-healing evidence spanning GI mucosal repair, vascular protection, and soft-tissue regeneration. BPC-157 demonstrates consistent cytoprotective activity in gastric and intestinal models — stabilizing mucosal barrier function, reducing inflammatory cytokine cascades, and promoting angiogenesis. These GI-protective effects are the direct mechanistic basis for using BPC-157 as a co-agent during semaglutide administration to mitigate nausea and mucosal irritation.

Sports Health · 2025Open Access
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review →

Vasireddi N, Hahamyan H, Salata MJ, et al.

The most current systematic review of BPC-157 across 36 studies in musculoskeletal and sports medicine contexts. BPC-157 consistently promoted healing of muscle, tendon, and connective tissue by upregulating growth factors and modulating FAK-paxillin, VEGFR2-Akt-eNOS, and nitric oxide signaling. These same tissue-repair pathways provide the rationale for using BPC-157 to counter lean-mass and connective-tissue degradation that accompanies rapid GLP-1-driven weight loss.

The Lancet · 2021Paywalled
Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2) →

Davies M, Faerch L, Jeppesen OK, et al.

STEP 2 evaluated once-weekly semaglutide 2.4 mg in adults with overweight/obesity and type 2 diabetes (n=1,210). Mean weight loss was 9.6% over 68 weeks. GI adverse events were again the primary tolerability concern, with nausea and diarrhea the most frequent reasons for dose reduction or study discontinuation. The consistent GI tolerability pattern across STEP 1 and STEP 2 reinforces the relevance of GI-protective adjuncts in research protocols.

Weight LossGLP-1 AgonistGI ProtectionLean MassCombination BlendPreclinicalWADA S0

Related Peptides

SemaglutideBPC-157TirzepatideCagrilintide

Related Blends

Tirzepatide + BPC-157Wolverine Stack

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

We may earn commissions from peptide vendor affiliate links.

Have a question about Semaglutide + BPC-157? Send us an email →

For educational and research purposes only. Not medical advice. Not for human use.